Table 3. Mepolizumab population pharmacodynamic parameter estimates from the population pharmacokinetic/pharmacodynamic analysis.
| Parameters | Estimate (95% CI) | BSV |
|---|---|---|
| KRO (GI/L) | 0.710 (0.642 – 0.784) | 38.5% |
| KOUT (/day) | 0.414 (0.297 – 0.578) | NA |
| IC50 (ng/mL) | 1261 (878 – 1813) | NA |
| IMAX | 0.928 (0.875 – 0.959) | NA |
| BL covariate on KRO | 0.701 (0.544 – 0.858) | NA |
| RESIDUAL | 0.471 (0.419 – 0.518) | WSB (95% CI) 49.9% (43.8 – 55.5) |
KRO = blood eosinophils baseline; KOUT = blood eosinophils rate of elimination; IC50 = concentration inducing 50% of the maximum inhibitory effect; IMAX = maximum inhibitory effect; BL = baseline, BSV = between-subject variability; WSB = within-subject variability; NA = not applicable. WSB (95% CI) was calculated post-hoc. Residual error model: Y = F×exp(εi); 95% CI = estimate ± 1.96 × SE; SE = standard error; %CV = 100 × SQRT(exp(x)-1) with x = ETA or x = εi; ETA = variance.